Abeona Therapeutics (ABEO) Liabilities and Shareholders Equity (2010 - 2026)

Abeona Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $198.5 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 99.76% year-over-year to $198.5 million; the TTM figure through Mar 2026 stood at $895.4 million (up 93.44% YoY), while the FY2025 annual figure was $219.6 million, up 101.57% from the prior year.
• Liabilities and Shareholders Equity was $198.5 million for Q1 2026 at Abeona Therapeutics, down from $219.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $246.2 million in Q2 2025 to a low of $38.8 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $110.2 million across 5 years, with a median of $74.8 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity slumped 67.43% in 2022, then surged 150.24% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $64.2 million in 2022, then fell by 0.33% to $64.0 million in 2023, then soared by 70.2% to $108.9 million in 2024, then soared by 101.57% to $219.6 million in 2025, then slipped by 9.6% to $198.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $198.5 million (Q1 2026), $219.6 million (Q4 2025), and $231.1 million (Q3 2025), per Business Quant data.